Navigation Links
Florida Attorney Gary M. Farmer, Jr. Settles Third Whistleblower Drug Case for $1.27 Billion
Date:11/5/2013

FORT LAUDERDALE, Fla., Nov. 5, 2013 /PRNewswire/ -- South Florida consumer advocate and leading false claims attorney Gary M. Farmer, Jr., a partner with Farmer, Jaffe, Weissing, Edwards, Fistos & Lehrman, P.L., has successfully litigated his third major false claims case against a global pharmaceutical company. Today, the United States Department of Justice announced a settlement against pharmaceutical giant Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals Inc. Johnson & Johnson and Janssen will pay a total of $2.2 billion to state and federal entities, $1.27 billion of which consists of civil fines and restitution regarding the drug Risperdal®. As the lead whistle-blower to bring the false claims to the government's attention, Farmer's client will share in a portion of the civil recovery.

Risperdal® was FDA approved for schizophrenia, specific bipolar disorders and behavior problems in teenagers and children with autism. The company was charged with:

  • Promoting and marketing the drug to physicians for use "off-label" in children and the elderly for conditions such as ADHD, depression and dementia;
  • Falsely claiming that Risperdal® was safer and more effective than similar, cheaper drugs; and
  • Failing to adequately warning about the drug's possible side effects (diabetes and neurological problems).

Using falsified and misleading science and data, Janssen marketed Risperdal for these and other unapproved uses, specifically targeting pediatricians and nursing homes to prey upon vulnerable children and the elderly. Not only did Janssen know about but failed to disclose significant health risks associated with Risperdal, it affirmatively misrepresented Risperdal as being safe and without these known dangers and side-effects.

"This case clearly showed how Janssen Pharmaceutical was willing to put profits before people, and sales before safety," said attorney Gary Farmer. "In the endless pursuit of profit Johnson & Johnson and Janssen aggressively marketed their drug Risperdal® with no regard as to what happened to patients who used it, including the most vulnerable patients – children and the elderly."

Whistleblower and client Vicki Starr approached Farmer regarding the illegal marketing practices of Risperdal® and filed suit under the Civil False Claims Act (31 U.S.C. Section 3729 et seq.). Also known as the Informer's Act, this statute allows private individuals to sue companies that knowingly defraud the U.S. and/or state governments. It also protects whistleblowers from demotion, suspension, harassment and discrimination for cooperating with the investigation of their employer. Starr not only witnessed this from the pharmaceutical perspective, as a former employee, but was also the target of the pharmaceutical company's marketing in her later employment as a medical director of a nursing home.

Farmer was also spearheaded a drug case against pharmaceutical giant, Eli Lilly, which was resolved in a record setting $1.42 billion settlement in January 2009. In 2010, he successfully settled another false claims case against AstraZeneca for $520 million in fines and restitution. Farmer is nationally-recognized as a civil justice attorney and consumer advocate and is considered one of Florida's leading consultants on qui tam law and litigation.

Farmer, Jaffe, Weissing, Edwards & Lehrman, P.L., a Fort Lauderdale Litigation firm, focuses on Consumer Class Actions, Personal Injury, Wrongful Death, and Whistleblower Suits (qui tam). The firm is headquartered at 425 N. Andrews Avenue, Suite 2 and may be reached at (800) 400-1098. Additional information about Gary Farmer or the firm may be obtained at http://www.pathtojustice.com or http://www.linkedin.com/pub/gary-farmer/13/863/b26 .

Contact
Gary Farmer - Farmer, Jaffe, Weissing, Edwards, Fistos & Lehrman, P.L.
(800) 400-1098


'/>"/>
SOURCE Farmer, Jaffe, Weissing, Edwards, Fistos & Lehrman, P.L.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Profil Institute Partners with Florida Hospital to Establish East Coast Center for Clinical Metabolic Research
2. Arthritis Associates of South Florida Acquires Access to Patient Health History Faster with Digital Pen Technology from Anoto and NextGen Healthcare
3. Spine Pain Management Opens Two Additional Affiliate Diagnostic Centers in Florida
4. Floridas Stop-Sale System Achieves Significant Results In Battle Against Meth
5. Florida Cardiovascular Association Utilizes MedInformatix EMR Solution for Optimal Charting and Billing Workflow
6. Local Gastroenterologists First in South Florida to Offer Fecal Transplant
7. Bandages Plus, Inc. Doral, Florida has been acquired by The Morrissey Group, LLC
8. Florida Blue Awarded Certified Center of Excellence by BenchmarkPortal for Second Consecutive Year
9. Now Available in South Florida: CentraSight Treatment Program Offers New Hope for Patients with End-Stage Macular Degeneration
10. Only Podiatric Surgeon In S. Florida That Performs In-Office Ultrasound Imaging On Foot & Ankle Problems Saving Patients Over $1,000 In MRI Expenses & Extra Trip To Hospital
11. New Florida Peptides Site offering CJC-1295, GHRP-6, Sermorelin and more!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... new report "Global Anti-Bacterial Drugs Market Assessment & Forecast: 2015 - ... the North America continued to lead global ... translated into revenues worth US$ 16,907.3 million. ... Asia-Pacific , Latin America , ... anti-bacterial market is inclined towards North America ...
(Date:2/8/2016)... -- Respiratory Devices - Medical Devices Pipeline Assessment, ... report, " Respiratory Devices - Medical Devices Pipeline ... Devices currently in pipeline stage. The report ... comparative analysis of the products at various stages ... in the pipeline product development. It also provides ...
(Date:2/8/2016)... and FAIRFIELD, N.J. , Feb. 8, ... Pharmaceuticals, Inc. (Medimetriks) today announced that they have entered ... commercialization rights for OPA-15406 in the U.S. and ... manufacturing rights.  OPA-15406 is a topical, non-steroidal phosphodiesterase IV ... --> --> In ...
Breaking Medicine Technology:
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... Techniques.” The guide will ensure lab personnel have a basic understanding of the ... lab measurement protocols. Enhanced understanding will help them reduce waste and rework to ...
(Date:2/9/2016)... California (PRWEB) , ... February 09, 2016 , ... i2i ... one of the highest preliminary data vendors in the latest KLAS report, Population Health ... i2i has led the developing market for population health management (PHM). The latest ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... with BASF Human Nutrition into the Food & Beverage and ... been BASF’s channel partner throughout Canada and USA geographies east of the Rocky ...
(Date:2/8/2016)... ... February 08, 2016 , ... Brenton Engineering , powered ... and flow wrapped products at WestPack 2015, February 9-11, in Anaheim, California. This ... to semi-automatic or fully-automatic case packing with a small footprint, rugged, highly flexible, ...
(Date:2/8/2016)... ... 08, 2016 , ... Local insurance agency Dennis Fuller & ... has initiated a fundraiser for a two year old little girl named Bella, ... To support this beautiful child who is facing life’s journey without her loving ...
Breaking Medicine News(10 mins):